Oxaliplatin

Generic Name: Oxaliplatin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄N_₂O_₄Pt

CAS Number: 61825-94-3

Unique Ingredient Identifier: 04ZR38536J

Background: Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin.

Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer. This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer.

Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.

Indication: Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions: Advanced Colorectal Cancer, Stage III Colon Cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-02

Last Posted Date: 2011-08-03

Lead Sponsor: Mayo Clinic

Registration Number: NCT00005068

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2004-04-02

Last Posted Date: 2011-04-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005860

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX regimen
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2004-03-11

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00016978

Locations: 🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States
🇺🇸
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
🇺🇸
Rapid City Regional Hospital, Rapid City, South Dakota, United States

and more 21 locations

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

Phase 3

Completed

Conditions: Adenocarcinoma of the Colon
Stage III Colon Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: Locally Directed Therapy
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: fluorouracil
Biological: cetuximab

First Posted Date: 2004-03-10

Last Posted Date: 2020-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3397

Registration Number: NCT00079274

Locations: 🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸
Hematology and Oncology Associates, Chicago, Illinois, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 872 locations

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

First Posted Date: 2004-03-08

Last Posted Date: 2009-01-13

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Registration Number: NCT00006115

Locations: 🇫🇷
Hopital Tenon, Paris, France
🇫🇷
Hopital Claude Gallien, Quincy Sous Senart, France
🇫🇷
Hopital Saint Antoine, Paris, France

and more 13 locations

Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-03-04

Last Posted Date: 2013-01-31

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT00005035

Locations: 🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States

and more 8 locations

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

First Posted Date: 2004-02-16

Last Posted Date: 2014-01-06

Lead Sponsor: Sanofi

Registration Number: NCT00008281

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸
Medical Oncology Internal Medicine, Los Angeles, California, United States

and more 129 locations

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

Interventions: Drug: oxaliplatin

First Posted Date: 2004-02-12

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT00004203

Locations: 🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 11 locations

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Phase 3

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: 5-FU
Drug: cetuximab
Drug: irinotecan
Drug: leucovorin
Drug: oxaliplatin

First Posted Date: 2004-02-11

Last Posted Date: 2018-05-16

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 238

Registration Number: NCT00077233

Locations: 🇺🇸
Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

and more 74 locations

Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2004-02-02

Last Posted Date: 2021-02-17

Lead Sponsor: UNICANCER

Registration Number: NCT00006050

Locations: 🇫🇷
Institut J. Paoli and I. Calmettes, Marseille, France
🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy